Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications-or even more?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27181771.
- Also identified by DOI 10.1016/j.kint.2016.02.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Vascular calcification and kidney fibrosis are 2 important features of chronic kidney disease. Bone morphogenetic proteins/growth differentiation factors and their receptors are implicated in the pathogenesis of both processes. Modulation of the bone morphogenetic protein/growth differentiation factor pathways by a soluble chimeric protein that contains the activin receptor IIA (ActRIIA) domain and acts as an ActRIIA ligand trap for activin and other ligands could become a new therapeutic strategy for vascular calcification and kidney fibrosis in chronic kidney disease.
Medical subject headings
- Activin Receptors
- Activins